Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 10,492 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-927, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Infrequent Bowel Movements
Interventions: B. longum, Placebo; Dietary Supplement
Lead sponsor: Morinaga Milk Industry Co., LTD; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions: SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab; Radiation · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Prostate Carcinoma
Interventions: Computed Tomography, Flotufolastat F-18 Gallium, Medical Device Usage and Evaluation, Positron Emission Tomography; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine, COVID-19 Vaccine
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Hemochromatosis
Interventions: Phlebotomy; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Hypertension, Blood Pressure
Interventions: Blood Pressure Cuff, EKG, PPG; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Retinitis Pigmentosa
Interventions: Electro-acupuncture, Laser Acupuncture, Transcorneal Electrical Stimulation, Sham Electro-acupuncture, Sham laser acupuncture, Sham transcorneal electrical stimulation; Device
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Duarte, California • Irvine, California • La Jolla, California + 28 more

Conditions: Colorectal Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 49 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more

Conditions: Hidradenitis Suppurativa
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more

Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Ocular Melanoma
Interventions: Data collection; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Clostridioides Difficile Infection
Interventions: LMN-201, Placebo; Drug
Lead sponsor: Lumen Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 26
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Stress Disorders, Post-Traumatic, Combat Stress Disorders, Animal-Human Bonding
Interventions: PTSD Service Dog; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Blood and Lymphatic Diseases
Interventions: BIVV003, ST-400; Drug
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 7
States / cities: Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more

Conditions: Classical Hodgkin Lymphoma
Interventions: Itacitinib, Everolimus; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Feeding Tube, Children With Medical Complexity, Tracheostomy, Feeding Disorder, Infancy or Early Childhood
Interventions: Tube weaning therapy intervention, Feeding Group; Other
Lead sponsor: University of Chicago; Other
Eligibility: Up to 3 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus (Type 2)
Interventions: Speak Up! Video; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Hines, Illinois • Crown Point, Indiana

Conditions: Arthroplasty, Replacement, Shoulder
Interventions: Reverse Total Shoulder; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 22 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Mezigdomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 33
States / cities: Mobile, Alabama • Cerritos, California • Irvine, California + 28 more

Search by objective public record fields.

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer

SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

Treatment of Hemochromatosis

Vital Signs Blood Pressure Trial

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

A Study of Mosliciguat in PH-ILD

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Eye Plaque Brachytherapy for Ocular Melanoma

LMN-201 for Prevention of C. Difficile Infection Recurrence

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Multi-site, Longitudinal Trial Evaluating the Efficacy, Mechanisms, and Moderators of Service Dogs for Military Veterans With PTSD

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

Itacitinib + Everolimus in Hodgkin Lymphoma

Let's E.A.T.! (Eating With Assistive Technology): An Intervention to Support Children With Feeding Tubes and Tracheostomies

Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial

INHANCE Stemless Reverse Shoulder IDE

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)